The global anti-rheumatics market size reached US$ 64.5 Billion in 2023. Looking forward, the publisher expects the market to reach US$ 80.4 Billion by 2032, exhibiting a growth rate (CAGR) of 2.48% during 2023-2032. The increasing aging population across the globe, expansion of hospitals, clinics, and other healthcare facilities, and the expanding partnerships between large pharmaceutical companies and healthcare centers are some of the major factors propelling the market growth.
Anti-rheumatics are medications used to treat diseases affecting the joints, muscles, and connective tissues. They help reduce inflammation, pain, and stiffness, and slow the progression of the disease. They are available in various classes, including non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), and biologics. They can be administered orally, subcutaneously and intravenously into the body. They target the underlying mechanisms that lead to tissue damage and inflammation. They are generally prescribed after a thorough diagnosis and are used in combination for optimum results.
The rising prevalence of rheumatic diseases due to unhealthy dietary patterns and lack of physical activity represent one of the key factors catalyzing the demand for effective treatments. Additionally, continuous development in drug delivery systems, like nanoparticle-based carriers or time-release capsules, is enhancing the efficacy and convenience of anti-rheumatic medications.
Apart from this, the growth of telehealth services is enabling better disease management and easier prescription refills, promoting consistent use of anti-rheumatic drugs. Furthermore, the expansion of healthcare systems into emerging markets is making anti-rheumatic medications more accessible to underserved populations. Moreover, advancements in genomics and personalized medicine are allowing for more targeted treatments and improving the effectiveness of anti-rheumatic medications.
Additionally, governing authorities and healthcare systems of various countries are recognizing this growing need and are increasing healthcare budgets to address the challenges of an aging society. Pharmaceutical companies are also focusing their research and development efforts on creating more effective and safer anti-rheumatic medications. As a result, the market for these drugs is expected to grow substantially in the coming years.
Furthermore, the governing authorities of several countries are organizing public health campaigns, which is offering a favorable market outlook. Moreover, the development of advanced diagnostic tools has made it easier for healthcare professionals to identify rheumatic diseases at an early stage. This proactive approach enhances the market demand for anti-rheumatics, as timely intervention necessitates medication for symptom management and disease modification.
This often involves launching products in new geographical markets, increasing production capacities, or diversifying supply chains to ensure more reliable distribution. Furthermore, various companies are using analytics to identify market trends, patient preferences, and treatment outcomes. Moreover, they are investing in educational programs for healthcare providers, patients, and the public.
The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:
2. What is the expected growth rate of the global anti-rheumatics market during 2024-2032?
3. What are the key factors driving the global anti-rheumatics market?
4. What has been the impact of COVID-19 on the global anti-rheumatics market?
5. What is the breakup of the global anti-rheumatics market based on the type?
6. What is the breakup of the global anti-rheumatics market based on the drug class?
7. What is the breakup of the global anti-rheumatics market based on the route of drug administration?
8. What is the breakup of the global anti-rheumatics market based on the distribution channel?
9. What are the key regions in the global anti-rheumatics market?
10. Who are the key players/companies in the global anti-rheumatics market?
Anti-rheumatics are medications used to treat diseases affecting the joints, muscles, and connective tissues. They help reduce inflammation, pain, and stiffness, and slow the progression of the disease. They are available in various classes, including non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), and biologics. They can be administered orally, subcutaneously and intravenously into the body. They target the underlying mechanisms that lead to tissue damage and inflammation. They are generally prescribed after a thorough diagnosis and are used in combination for optimum results.
The rising prevalence of rheumatic diseases due to unhealthy dietary patterns and lack of physical activity represent one of the key factors catalyzing the demand for effective treatments. Additionally, continuous development in drug delivery systems, like nanoparticle-based carriers or time-release capsules, is enhancing the efficacy and convenience of anti-rheumatic medications.
Apart from this, the growth of telehealth services is enabling better disease management and easier prescription refills, promoting consistent use of anti-rheumatic drugs. Furthermore, the expansion of healthcare systems into emerging markets is making anti-rheumatic medications more accessible to underserved populations. Moreover, advancements in genomics and personalized medicine are allowing for more targeted treatments and improving the effectiveness of anti-rheumatic medications.
Anti-Rheumatics Market Trends/Drivers:
Rising aging population
The increasing aging population, which is more susceptible to joint disorders, such as osteoarthritis and rheumatoid arthritis, represents one of the key factors augmenting the market growth. Moreover, older populations often have multiple health conditions that can exacerbate rheumatic diseases, thus requiring more complex and long-term treatment strategies.Additionally, governing authorities and healthcare systems of various countries are recognizing this growing need and are increasing healthcare budgets to address the challenges of an aging society. Pharmaceutical companies are also focusing their research and development efforts on creating more effective and safer anti-rheumatic medications. As a result, the market for these drugs is expected to grow substantially in the coming years.
Strategic collaborations and mergers
The increasing number of strategic collaborations, mergers, and acquisitions (M&A) among pharmaceutical companies and healthcare facilities is another major factor contributing to the market growth. They often include knowledge-sharing agreements, making it easier to navigate regulatory hurdles and reducing the time-to-market for new medications. Additionally, the expanding partnerships between large pharmaceutical companies and biotech startups result in the faster development and commercialization of new anti-rheumatic drugs. Apart from this, it facilitates research and development (R&D) activities to introduce more advanced drugs. Furthermore, these collaborations promote an easy supply of anti-rheumatic drugs to reach previously untapped markets, contributing to global market growth.Rising awareness about early diagnosis and prevention
The rising awareness among individuals about the benefits of early diagnosis and prevention of rheumatoid diseases is strengthening the growth of the market. Early diagnosis allows for more effective management of the disease, often requiring the use of anti-rheumatic drugs. Additionally, the increasing reliance of people on social media channels promoting medical education is positively influencing the market.Furthermore, the governing authorities of several countries are organizing public health campaigns, which is offering a favorable market outlook. Moreover, the development of advanced diagnostic tools has made it easier for healthcare professionals to identify rheumatic diseases at an early stage. This proactive approach enhances the market demand for anti-rheumatics, as timely intervention necessitates medication for symptom management and disease modification.
Anti-Rheumatics Industry Segmentation:
The publisher provides an analysis of the key trends in each segment of the global anti-rheumatics market report, along with forecasts at the global regional, and country levels from 2024-2032. Our report has categorized the market based on type, drug class, route of drug administration and, distribution channel.Breakup by Type:
- Prescription-based Drugs
- Over-the-Counter Drugs
Prescription-based drugs account for the majority of the market share
Breakup by Drug Class:
- Disease Modifying Anti-Rheumatics Drugs (DMARD's)
- Nonsteroidal Anti-Inflammatory Drugs (NSAID's)
- Corticosteroids
- Uric Acid Drugs
- Others
Disease modifying anti-rheumatics drugs (DMARD's) hold the largest share in the industry
Breakup by Route of Drug Administration:
- Oral
- Parenteral
- Others
Parenteral represents the leading market segment
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- E-Commerce
Hospital pharmacies exhibit a clear dominance in the market
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
North America leads the market, accounting for the largest anti-rheumatics market share
Competitive Landscape:
Companies are investing heavily in the development of new anti-rheumatic drugs, targeting existing and emerging therapeutic mechanisms. Additionally, many companies are entering into partnerships, mergers, and acquisitions. These strategic collaborations often involve sharing technology, resources, and market channels. Apart from this, they are also focusing on expanding market access through various channels.This often involves launching products in new geographical markets, increasing production capacities, or diversifying supply chains to ensure more reliable distribution. Furthermore, various companies are using analytics to identify market trends, patient preferences, and treatment outcomes. Moreover, they are investing in educational programs for healthcare providers, patients, and the public.
The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca plc
- Biogen Inc.
- Bristol-Myers Squibb Company
- Celltrion Inc.
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Johnson & Johnsons
- Pfizer Inc.
- Sanofi SA
Recent Developments:
- In July 2023, AbbVie Inc. announced that the first patient has been dosed in the Phase 3 Step-Up HS study to evaluate upadacitinib (RINVOQ®) in adults and adolescents with moderate to severe hidradenitis suppurativa (HS) symptoms and have failed anti-tumor necrosis factor (TNF) therapy and one approved non-anti-TNF inhibitor therapy for HS.1
- In November 2022, Amgen Inc. announced that clinical and real-world data across its broad portfolio of established treatments and pipeline assets will be presented at the annual American College of Rheumatology Convergence (ACR).
- In September 2022, Biogen Inc. announced that the European Medicines Agency (EMA) had accepted the Marketing Authorization Application (MAA) for BIIB800, a biosimilar candidate referencing RoACTEMRA®1 (tocilizumab), an anti-interleukin-6 receptor monoclonal antibody.
Key Questions Answered in This Report
1. What was the size of the global anti-rheumatics market in 2023?2. What is the expected growth rate of the global anti-rheumatics market during 2024-2032?
3. What are the key factors driving the global anti-rheumatics market?
4. What has been the impact of COVID-19 on the global anti-rheumatics market?
5. What is the breakup of the global anti-rheumatics market based on the type?
6. What is the breakup of the global anti-rheumatics market based on the drug class?
7. What is the breakup of the global anti-rheumatics market based on the route of drug administration?
8. What is the breakup of the global anti-rheumatics market based on the distribution channel?
9. What are the key regions in the global anti-rheumatics market?
10. Who are the key players/companies in the global anti-rheumatics market?
Table of Contents
1 Preface3 Executive Summary12 Value Chain Analysis14 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Anti-Rheumatics Market
6 Market Breakup by Type
7 Market Breakup by Drug Class
8 Market Breakup by Route of Drug Administration
9 Market Breakup by Distribution Channel
10 Market Breakup by Region
11 SWOT Analysis
13 Porters Five Forces Analysis
15 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca plc
- Biogen Inc.
- Bristol-Myers Squibb Company
- Celltrion Inc.
- Eli Lilly
- Company
- F. Hoffmann-La Roche AG
- Johnson & Johnsons
- Pfizer Inc.
- Sanofi SA
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 140 |
| Published | August 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 64.5 Billion |
| Forecasted Market Value ( USD | $ 80.4 Billion |
| Compound Annual Growth Rate | 2.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
